logo

English
                 

        An E-Mail came from one of my classmate's son who is a doctor appearing in the NBC interviews.
        A review of studies in the medical journal Lancet suggests the benefits of aspirin may outweigh the risks.
        Aspirin users have a 36 percent lower risk for having their cancers spread
        and those who take aspirin have a 38 percent lower chance of developing colorectal cancer.
        NBC’s Dr. Nancy Snyderman reports.


        http://www.msnbc.msn.com/id/3032619/vp/46801645#46801645

        The following article backs up the NBC reports.

 

The Lancet, Volume 377, Issue 9759, Pages 31 - 41, 1 January 2011

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

Prof Peter M Rothwell FMedSci, Prof F Gerald R Fowkes FRCPE b, Prof Jill FF Belch FRCP c, Hisao Ogawa MD d, Prof Charles P Warlow FMedSci e, Prof Tom W Meade FRS f

Summary

Background

Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.

Methods

We used individual patient data from all randomised trials of daily aspirin versus no aspirin with mean duration of scheduled trial treatment of 4 years or longer to determine the effect of allocation to aspirin on risk of cancer death in relation to scheduled duration of trial treatment for gastrointestinal and non-gastrointestinal cancers. In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries.

Results

In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68—0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years' follow-up (all cancers, hazard ratio [HR] 0·66, 0·50—0·87; gastrointestinal cancers, 0·46, 0·27—0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72—0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54—0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54—0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26—0·66, p=0·0001). The latent period before an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, and prostate cancer. For lung and oesophageal cancer, benefit was confined to adenocarcinomas, and the overall effect on 20-year risk of cancer death was greatest for adenocarcinomas (HR 0·66, 0·56—0·77, p<0·0001). Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age—the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42—11·74) at age 65 years and older.

Interpretation

Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.

Funding

None.
No. Subject Date Author Last Update Views
Notice How to write your comments onto a webpage [2] 2016.07.06 운영자 2016.11.20 18173
Notice How to Upload Pictures in webpages 2016.07.06 운영자 2018.10.19 32321
Notice How to use Rich Text Editor [3] 2016.06.28 운영자 2018.10.19 5901
Notice How to Write a Webpage 2016.06.28 운영자 2020.12.23 43816
483 [Medical]Statins For Atrial Fibrillation(Internal Medicine News) 2013.06.07 이한중*65 2013.06.07 3827
482 [Medical] Invokana Outperformed Januvia in Type 2 Diabetes [1] 2013.06.30 이한중*65 2013.06.30 3814
481 [Medical Column] 26. 비만과 건강-2 2012.01.05 이종구*57 2012.01.05 3783
480 [Medical] Brain Initiative Unveiled 2013.04.14 이한중*65 2013.04.14 3714
479 Great News, Cancer Therapy 2013.07.14 김영철*61 2013.07.14 3681
478 [Medical Column] 25. 비만과 건강-1 [1] 2012.01.04 이종구*57 2012.01.04 3647
477 The Link Between Smoking and Crohn's Disease [1] 2013.05.21 운영자 2013.05.21 3637
476 Hepatitis C, Curative Oral Drugs Coming [2] 2013.11.04 이한중*65 2013.11.04 3619
475 Re-evaluation of "Aspirin a day" [2] 2010.10.15 운영자 2010.10.15 3613
474 [Medical] Interpreting LDL Cholesterol levels Correctly [2] 2013.06.17 이한중*65 2013.06.17 3545
473 [Medical Column] 소금은 얼마나 먹어야하나 [2] 2012.04.04 이종구*57 2012.04.04 3481
472 [Medical Column] 14. 뇌졸증-2 2011.10.07 이종구*57 2011.10.07 3354
» [Medical Journal] Aspirin reduces cancer death [2] 2012.03.21 Rover 2012.03.21 3345
470 Vitamin D blood level and UV radiation [2] 2013.06.11 김영철*61 2013.06.11 3303
469 [Medical Journal] Aspirin reduces Colon Cancer 2012.03.21 Rover 2012.03.21 3300
468 Why Your DNA Isn't Your Destiny - TIME magazine [4] 2010.01.11 운영자 2010.01.11 3293
467 [Medical] Juicing can be dangerous. [1] 2013.08.28 이한중*65 2013.08.28 3279
466 [Medical Column] 15. 뇌졸증-3 2011.10.12 이종구*57 2011.10.12 3266
465 [Medical] Why So Hard To Wash Hands? (NY Times) 2013.05.29 이한중*65 2013.05.29 3243
464 [Medical] Potential Adverse CV Effects of Excessive Excercise [1] 2012.07.01 이한중*65 2012.07.01 3212